Strong scientific consensus supports the market-implied 94.5% probability of no hantavirus vaccine available in 2026, as all candidates remain in early preclinical or initial Phase I stages with no late-stage trials underway. Promising mRNA platforms from Moderna-Korea University and UTMB have shown protection in animal models against strains like Andes virus, including single-dose efficacy, yet these require extensive human testing, manufacturing scale-up, and regulatory review that standard timelines place years away. Existing inactivated vaccines in China and South Korea target different hantaviruses and lack approval or broad efficacy data for Americas strains. Heightened attention from the 2026 cruise ship outbreak has spurred funding discussions but not accelerated any candidate to approval thresholds. A realistic challenge would require unprecedented emergency authorization or massive new investment to compress development, though current evidence shows no such pathway active by year-end.